Clemens Küpper

Clemens Küpper

Auto-generated profile, based on publicly available information

Clemens Küpper

Department of Neurology, Ludwig Maximilians University (LMU), Munich, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
TKThomas Klopstock
Thomas Klopstock
FTFernando Tricta
Fernando Tricta
LNLynne Neumayr
Lynne Neumayr
IKIvan Karin
Ivan Karin
GZGiovanna Zorzi
Giovanna Zorzi
EVElliott Vichinsky
Elliott Vichinsky

1 October 2018 in Stroke
Verified
Journal Article
Closed access
SNSimon Nagel
Simon Nagel
MBMehdi Bouslama
Mehdi Bouslama
LKLars U. Krause
Lars U. Krause
CKClemens Küpper
Clemens Küpper
MMMirko Messer
Mirko Messer
RNRaul G. Nogueira
Raul G. Nogueira
Background and Purpose—: We aimed to describe the safety and efficacy of immediate mechanical thrombectomy (MT) in patients with large vessel occlusions and low National Institutes of Health Stroke Scale (NIHSS) versus best medical management. Methods—: Patients from prospectively collected databases of 6 international comprehensive stroke centers with large vessel occlusions (distal intracranial internal carotid, middle cerebral artery-M1 and M2 segments, or basilar artery with or without tandem occlusions) and NIHSS 0 to 5 were identified and divided into 2 groups for analysis: immediate MT or initial best medical management which included rescue MT after neurological deterioration (best medical management-MT). Uni- and multivariate analyses and patient-level matching for age, baseline NIHSS, and occlusion site were performed to compare baseline and outcome variables across the 2 groups. The primary outcome was defined as good outcome (modified Rankin Scale score, 0–2) at day 90. Safety outcome was symptomatic intracranial hemorrhage as defined by the ECASS (European Cooperative Acute Stroke Study) II and mortality at day 90. Results—: Compared with best medical management-MT (n=220), patients with immediate MT (n=80) were younger (65.3±13.5 versus 69.5±14.1; P =0.021), had more often atrial fibrillation (44.8% versus 28.2%; P =0.012), higher baseline NIHSS (4, 0–5 versus 3, 0–5; P =0.005), higher Alberta Stroke Program Early CT Score (10, 7–10 versus 10, 5–10; P =0.023), more middle cerebral artery-M1, and less middle cerebral artery-M2 (41.3% versus 21.9% and 28.8% versus 49.3%; P =0.016) occlusions. The adjusted odds ratio for good outcome was 3.1 (95% CI, 1.4–6.9) favoring immediate MT. In the matched analysis, there was a 14.4% absolute difference in good outcome (84.4% versus 70.1%; P =0.03) at day 90 favoring immediate MT. There were no safety concerns. Conclusions—: Our retrospective, pilot analysis suggests that immediate thrombectomy in large vessel occlusions patients with low NIHSS on presentation may be safe and has the potential to result in improved outcomes. Randomized clinical trials are warranted to establish the optimal management for this patient population.

1 February 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LKLaura S. Kremer
Laura S. Kremer
FDFelix Distelmaier
Felix Distelmaier
BABader Alhaddad
Bader Alhaddad
MHMaja Hempel
Maja Hempel
AIArcangela Iuso
Arcangela Iuso
THTobias B. Haack
Tobias B. Haack

1 March 2020 in Stroke
Verified
Journal Article
Closed access
PDF file
STSteffen Tiedt
Steffen Tiedt
MHMoriz Herzberg
Moriz Herzberg
CKClemens Küpper
Clemens Küpper
KFKatharina Feil
Katharina Feil
LKLars Kellert
Lars Kellert
FIfor the GSR Investigators*
for the GSR Investigators*
Background and Purpose—: Stroke etiology drives thrombus composition. We thus hypothesized that endovascular treatment shows different efficacy in cardioembolic versus noncardioembolic large-vessel occlusions (LVOs). Methods—: Procedural characteristics, grade of reperfusion, and functional outcome at discharge and 90 days were compared between patients with cardioembolic versus noncardioembolic LVO from the GSR-ET (German Stroke Registry–Endovascular Treatment; n=2589). To determine associations with functional outcome, adjusted odds ratios and 95% CIs were calculated using ordinal multivariable logistic regression models adjusting for potential baseline confounder variables. Results—: Endovascular treatment of cardioembolic LVO had a higher rate of successful reperfusion (85.6% versus 81.0%; P =0.002) and a higher rate of complete reperfusion after a single thrombectomy pass (45.7% versus 38.1%; P <0.001) compared with noncardioembolic LVO. Cardioembolic LVO was associated with better functional outcome at discharge (adjusted odds ratio, 1.61 [95% CI, 1.37–1.88]) and 90 days (adjusted odds ratio, 1.29 [95% CI, 1.09–1.53]). In mediation analysis, reperfusion explained 47% of the effect of etiology on functional outcome at discharge. Conclusions—: These results provide evidence for higher efficacy of endovascular treatment in cardioembolic LVO compared with noncardioembolic LVO.

16 December 2020 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
KFKatharina Feil
Katharina Feil
CKClemens Küpper
Clemens Küpper
STSteffen Tiedt
Steffen Tiedt
KDKonstantinos Dimitriadis
Konstantinos Dimitriadis
HMHerzberg Moriz
Herzberg Moriz
FIfor the GSR Investigators
for the GSR Investigators
Background and purpose: Up to 30% of infective endocarditis (IE) patients have ischemic stroke as a complication. Standard treatment with mechanical thrombectomy (MT) with or without intravenous thrombolysis for large vessel occlusion (LVO) has not been evaluated formally in these patients.Methods: Patients enrolled in the German Stroke Registry–Endovascular Treatment (GSR‐ET) between June 2015 and December 2019 were analyzed. Patients with stroke due to IE and patients with cardioembolic stroke and atrial fibrillation (AF) were compared using propensity score matching. Successful reperfusion was defined as modified Thrombolysis in Cerebral Infarction score = 2b–3. Modified Rankin Scale (mRS) = 0–2 at 3 months indicated good outcome.Results: Of 6635 patients, 55 patients (age = 69.0 ± 13.3 years, 43.6% female, median premorbid mRS (pmRS) = 1, interquartile range [IQR] = 0–1, National Institutes of Health Stroke Scale [NIHSS] = 15, IQR = 10–21) presented with septic embolic stroke due to IE and were compared to 104 patients (age = 66.5 ± 13.4 years, 39.4% female, pmRS = 0, IQR = 0–2, NIHSS = 16, IQR = 10–20) with cardioembolic stroke due to AF. Successful recanalization was achieved in 74.5% of endocarditis patients compared to 87.5% of controls (p = 0.039). Intracranial hemorrhage rates were comparable (30.9% vs. 21.6%, p = 0.175). Good functional outcome was 20.0% in patients with IE compared to 43.3% in matched patients (p = 0.006), with a significantly higher mortality (60.0% vs. 28.8%, p < 0.001). IE was strongly associated with poor outcome (odds ratio [OR] = 0.32, 95% confidence interval [CI] = 0.11–0.87, p = 0.03 for good outcome) and mortality (OR = 4.49, 95% CI = 1.80–10.68, p = 0.001).Conclusions: Although MT results in high successful recanalization rates with acceptable safety profile, patients with LVO stroke due to IE have poor outcome.

1 November 2019 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
CKClemens Küpper
Clemens Küpper
JHJohanna Heinrich
Johanna Heinrich
KKKatharina Kamm
Katharina Kamm
VBVeit Bücklein
Veit Bücklein
SRSimon Rothenfusser
Simon Rothenfusser
ASAndreas Straube
Andreas Straube
Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease of the CNS, which develops almost exclusively in immunocompromised patients and is caused by JC virus (JCV), a common polyomavirus. 1 So far, treatment efficacy is only modest if the compromised immune system cannot be restored. 2-4 A potential treatment target is the programmed cell death protein 1 (PD-1) whose expression on CD4 + and CD8 + T lymphocytes has been shown to be elevated in patients with PML. Moreover, blocking of the PD-1 receptor resulted in increased JCV-specific T-cell immune response in a subgroup of patients with PML. 5 Recently, pembrolizumab, a humanized monoclonal antibody directed against PD-1, was reported for the first time to be a promising option for PML with treatment responses in 6 of 9 patients. 6,7 Here, we describe another patient with PML who did not benefit from treatment with pembrolizumab.